Idera Stock Down, Study On Dermatomyositis Candidate Fails
Zacks Investment Research | Jun 12, 2018 10:28PM ET
Idera Pharmaceuticals Inc (NASDAQ:IDRA) announced that the phase II clinical study, evaluating its pipeline candidate, IMO-8400, for dermatomyositis — a rare inflammatory skin disease — fell short of meeting the primary endpoint.
Notably, the primary endpoint of the IMO-8400 study was to demonstrate a statistical significant change from baseline in the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) activity score, an outcome measure of skin disease severity, as compared to placebo.
Data from the study showed that in 30 eligible subjects, the mean CDASI activity score was in the severe range across all three treatment groups. This was despite background treatment with immunosuppressive drugs or systemic corticosteroid drugs administered to 17 of 30 patients.
The failure of this mid-stage study induced an almost 9% fall in Idera Pharmaceuticals stock on Tuesday Jun 12. In fact, shares of Idera Pharmaceuticals have decreased 16.6% compared with the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.